Streptococcus

Worldwide Poultry Probiotics Ingredients Industry to 2028 - Utilization of Protein-Rich Food Ingredients Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Food, Beverage, Retail, Animal, Meat, Immunity, Probiotic, Poultry, Lactobacillaceae, Health, Egg, Bacillus, Immune system, Growth, Farmer, Diet, Dietary supplement, Enzyme, Streptococcus, Animal husbandry, Agriculture, Bifidobacterium

The global poultry probiotics ingredients market is anticipated to grow at a substantial CAGR of 5.6 % during the forecast period.

Key Points: 
  • The global poultry probiotics ingredients market is anticipated to grow at a substantial CAGR of 5.6 % during the forecast period.
  • Expanding consumer demand for meat and eggs products, along with the utilization of protein-rich food ingredients, inclination towards dietary supplements are major factors that are probably going to drive poultry probiotic ingredients market growth.
  • The global poultry probiotics ingredients market is segmented based on Product, application.
  • Asia-Pacific region is projected to be the fastest growing market for poultry probiotics ingredients.

Dr. B Dental Solutions Launches Comprehensive Denture Care Kit for Full, Partial, Implant-Retained and Supported Dentures

Retrieved on: 
Friday, December 23, 2022
Fungus, Palate, Tea tree oil, Dentures, Coconut oil, Mouth, USB, ADA, Stomatitis, Liquid crystal, Candida albicans, Staphylococcus, Aloe, Family, Patient, Actinomyces, Pneumonia, American Dental Association, Vitamin E, Infection, Cleaning, Aloe vera, Xerostomia, Escherichia coli, Albicans, Tongue, Dentistry, Plaster, Streptococcus

Miami, Florida--(Newsfile Corp. - December 23, 2022) - Dr. B Dental Solutions has announced the launch of their care kit for denture wearers.

Key Points: 
  • Miami, Florida--(Newsfile Corp. - December 23, 2022) - Dr. B Dental Solutions has announced the launch of their care kit for denture wearers.
  • There are only three major companies in the US that offer both denture adhesives and denture cleansers, and even less worldwide.
  • Dr. B Dental Solutions is the only company to offer, in addition to superior denture adhesives and dental appliance cleaners, four unique new products with no competition that cater to the same market.
  • The care kit includes the following products:
    The Adhesadent denture adhesive is zinc-free and has no artificial colors or flavors.

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children

Retrieved on: 
Friday, January 6, 2023
Other Health, General Health, Family, Pharmaceutical, Consumer, Infectious Diseases, Parenting, Clinical Trials, Children, Baby, Maternity, Biotechnology, FDA, Health, Streptococcus, Priority review, PDUFA, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prescription Drug User Fee Act, IPD, Inc., NYSE, Development, Otitis media, PFE, Safety, Streptococcus pneumoniae, FDA, Senior, Vaccine, Pharmaceutical industry, Pfizer

Priority Review designation by the FDA reduces the standard sBLA review period by four months.

Key Points: 
  • Priority Review designation by the FDA reduces the standard sBLA review period by four months.
  • The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA on the 20vPnC vaccine application is anticipated in April 2023.
  • The FDA previously granted Pfizer’s 20vPnC Fast Track Designation in May 2017 and Breakthrough Therapy Designation in August 2020 for the pediatric indication for IPD.
  • These studies collectively enrolled approximately 3,500 infants and 800 children of all ages.

MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine

Retrieved on: 
Thursday, January 5, 2023
Communication, Boehringer Ingelheim, GBS, Food, European Medicines Agency, Drug development, III, Streptococcus, Drug, Ghent University, Streptococcus agalactiae, GSK, Risk, Disease, Development, Influenza, Pregnancy, US Food Sovereignty Alliance, Safety, FDA, Senior, Marketing, Fast Track, Pharmaceutical industry

COPENHAGEN, Denmark, Jan. 5, 2023 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the appointment of Lidia Oostvogels as Chief Medical Officer and provides an update on its novel GBS vaccine.

Key Points: 
  • COPENHAGEN, Denmark, Jan. 5, 2023 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the appointment of Lidia Oostvogels as Chief Medical Officer and provides an update on its novel GBS vaccine.
  • Lidia Oostvogels brings a wealth of experience in vaccine development with more than 25 years' experience in clinical development.
  • Oostvogels' experience will be instrumental as MinervaX progresses its GBS vaccine towards phase III clinical development.
  • Lidia Oostvogels, Chief Medical Officer of MinervaX, said: "I am hugely excited to join MinervaX and look forward to contributing to the further development of its GBS vaccine.

MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine

Retrieved on: 
Thursday, January 5, 2023
Communication, Boehringer Ingelheim, GBS, Food, European Medicines Agency, Drug development, III, Streptococcus, Drug, Ghent University, Streptococcus agalactiae, GSK, Risk, Disease, Development, Influenza, Pregnancy, US Food Sovereignty Alliance, Safety, FDA, Senior, Marketing, Fast Track, Pharmaceutical industry

COPENHAGEN, Denmark, Jan. 5, 2023 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the appointment of Lidia Oostvogels as Chief Medical Officer and provides an update on its novel GBS vaccine.

Key Points: 
  • COPENHAGEN, Denmark, Jan. 5, 2023 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the appointment of Lidia Oostvogels as Chief Medical Officer and provides an update on its novel GBS vaccine.
  • Lidia Oostvogels brings a wealth of experience in vaccine development with more than 25 years' experience in clinical development.
  • Oostvogels' experience will be instrumental as MinervaX progresses its GBS vaccine towards phase III clinical development.
  • Lidia Oostvogels, Chief Medical Officer of MinervaX, said: "I am hugely excited to join MinervaX and look forward to contributing to the further development of its GBS vaccine.

Global Bacteriophage Therapy Market Report 2022: Looming Threat of Antimicrobial Resistance Drives Research & Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Bacteria, Urinary tract infection, Biology, Subclinical infection, Geography, Staphylococcus aureus, Respiratory tract, Bacteriophage, Publication, Administration, USD, Genetically modified bacteria, Acinetobacter baumannii, Death, Preventive healthcare, Incidence, Research, Infection, Route of administration, World Health Organization, Growth, Salmonella, Degenerative disease, Therapy, Osteomyelitis, WHO, AMR, Pseudomonas aeruginosa, Centers for Disease Control and Prevention timeline, Disulfiram-like drug, Public health, Pseudomonas, Klebsiella pneumoniae, Traction, Escherichia coli, Pharmaceutical industry, Streptococcus

The "Bacteriophage Therapy Market: Distribution by Therapeutic Area, Route of Administration, and Geography: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bacteriophage Therapy Market: Distribution by Therapeutic Area, Route of Administration, and Geography: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • Given the afore-mentioned advantages of bacteriophage therapy and promising insights from the ongoing research, various clinical trials have been registered for the clinical evaluation of bacteriophage therapies.
  • In fact, with the widespread participation of stakeholders in the research and development of bacteriophage therapy, clinical studies evaluating bacteriophage therapy have increased at a growth rate of more than 30% over the last few years.
  • With increasing R&D efforts, promising clinical data, and financial support from investors, we anticipate the bacteriophage therapy market to witness notable growth in the mid to long term.

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology

Retrieved on: 
Thursday, December 1, 2022
COVID-19, Microcystic lymphatic malformation, United, LM, IL-6, Degenerative disease, Food and Drug Administration, Urology, Granulocyte colony-stimulating factor, TNF, Streptococcus, Food, Safety, LMS, CIS, Therapy, Granulocyte-macrophage colony-stimulating factor, Lymphocyte, Patient, IL-8, Monocyte, Neutrophil, Society, Cytokine, Neoplasm, Date, Annual general meeting, Streptococcus pyogenes, IL-12, Cancer, Cyst, Bladder cancer, FDA, Pharmaceutical industry, Risk management, NMIBC

The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).
  • In the initial dose escalation phase of the trial, patients will receive six weekly intravesical doses of TARA-002.
  • Bladder cancer is the 6th most common cancer inthe United States, with NMIBC representing approximately 80% of bladder cancer diagnoses.
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Global Human Vaccines Market Report 2022: Growing Prevalence of Emerging and Re-Emerging Infectious Diseases Fuels Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 30, 2022
Health, Pharmaceutical, Growth, Ansoff Matrix, Meningococcal disease, COVID-19, MMR, Vaccine, DTP, Shingles, Chickenpox, Risk, USD, Geography, Pneumococcal conjugate vaccine, SWOT, Viral vector vaccine, HPV, Market development, Streptococcus, Investment, Rotavirus

The Global Human Vaccines Market is segmented based on Technology, Type, Disease Indication, End-Users, and Geography.

Key Points: 
  • The Global Human Vaccines Market is segmented based on Technology, Type, Disease Indication, End-Users, and Geography.
  • By Technology, the market is classified into Conjugate Vaccines, Recombinant Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, and Viral Vector Vaccines.
  • The report presents a detailed Ansoff matrix analysis for the Global Human Vaccines Market.
  • The analyst analyses the Global Human Vaccines Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

LexaGene Successfully Completes Statement of Work for BioPharma Company

Retrieved on: 
Tuesday, November 22, 2022
COVID-19, Staphylococcus, LXG, Streptococcus, Escherichia coli, Risk, TSX Venture Exchange, Legislation, System, Gold, PCR, SEDAR, News, Genetic testing, Mycoplasma, OTCQB, Safety, Medical device, Cryptocurrency, Risk management, Cutibacterium

Furthermore, the data proved the MiQLab System is comparable to gold standard techniques performed by skilled scientists.

Key Points: 
  • Furthermore, the data proved the MiQLab System is comparable to gold standard techniques performed by skilled scientists.
  • The study was conducted mainly at LexaGene except for using proprietary materials from the biopharma company, as these tests were performed by employees of the biopharma company at their location using their recently purchased MiQLab System.
  • For more information about LexaGene and the MiQLab System, please visit www.lexagene.com or follow us on Twitter and LinkedIn .
  • LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of biological contaminants, pathogens and other molecular markers.

Global Probiotic and Prebiotic Yogurt Market Report 2022: Increased Yogurt Consumption Worldwide Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, November 14, 2022
Food, Beverage, Retail, Institute for Health Metrics and Evaluation, Milk, Ageing, Streptococcus thermophilus, Public Health Foundation of India, Bacteria, ICMR, Supermarket, Nutritional science, Lactic acid, Seefeld Nordic Competence Centre, BMI, Body mass index, China Health and Nutrition Survey, Medical research, Indian Council of Medical Research, Overweight, USD, Research, Streptococcus, Probiotic, Application, Yogurt, National Diet, Type 2 diabetes, Sugar, Estimation, Statistics, Evaluation, Risk, Health, Dietary supplement, Gum arabic

The "Global Probiotic and Prebiotic Yogurt Market, by Type, by Application, Estimation & Forecast, 2017-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Probiotic and Prebiotic Yogurt Market, by Type, by Application, Estimation & Forecast, 2017-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global probiotic and prebiotic yogurt market held a market value of USD 26.96 billion in 2021 and is projected to reach USD 49.76 billion by the year 2030.
  • The market volume for probiotic and prebiotic yogurt industry accounts to be 9,160.71 kilo tons in 2021, with a growth rate of 6.43% over the forecast period.
  • The market for probiotic and prebiotic yogurt is booming owing to the rising yogurt consumption, increasing research indicating the benefits of yogurt, and the rising market players.